EBIO - Eleven Biotherapeutics, Inc.

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE4 months ago

    Biotech Company, ENDV Should Be On Everyone's Watchlist

    HENDERSON, NV / ACCESSWIRE / June 19, 2018 / ENDV officially announced the enrollment of their first patient in a clinical study at the University of New Mexico Health Sciences Center that will evaluate the effects of Pulsed Electromagnetic Fields (PEMF) on reducing brain injury, blood-brain-barrier and inflammation biomarkers in the cerebrospinal fluid and blood in patients with brain injury who are or have been fitted to an external ventricular drain. Funding for the study has been secured via the Company's senior secured Series C Preferred Stock financing. With the recent advancement of companies who specialize in brain injuries and trauma advancing at a tremendous rate there is plenty of reason for optimism.

  • ACCESSWIRE5 months ago

    Blog Exposure - ADMA Biologics Received US Patent for Treating Respiratory Infections

    LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ADMA as the Company's latest news hit the wire. On May 16, 2018, the New Jersey-based biopharmaceutical Company announced that the United States Patent and Trademark Office has issued to ADMA US Patent No. 9,969,793 covering methods of treating respiratory infections. Active-Investors.com is currently working on the research report for Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), which also belongs to the Healthcare sector as the Company ADMA Biologics.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and VIVUS

    NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Eleven Biotherapeutics and VIVUS, Inc. were two biotech stocks to see big gains in Wednesday's trading session. VIVUS reported first quarter earnings earlier this month and recently announced an agreement to acquire all rights to Janssen's exocrine pancreatic insufficiency drug, pancreaze, in the United States and Canada. Janssen is a subsidiary of Johnson & Johnson.

  • Business Wire5 months ago

    Eleven Biotherapeutics Announces Corporate Name Change to Sesen Bio

    Eleven Biotherapeutics, Inc. (EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that the company is changing its name to Sesen Bio, Inc. Sesen Bio will trade under the new Nasdaq ticker symbol “SESN,” effective on May 17, 2018. The new website for Sesen Bio is www.sesenbio.com. Additionally, the company announced the appointments of Hagop Youssoufian, M.Sc., M.D. as senior medical advisor and Madhu Anant M.Sc., Ph.D., RAC as vice president of regulatory affairs.

  • Business Wire5 months ago

    Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates

    Eleven Biotherapeutics, Inc. , a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today reported pipeline updates and operating results for the quarter ended March 31, 2018.

  • Implied Volatility Surging for Eleven Biotherapeutics (EBIO) Stock Options
    Zacks6 months ago

    Implied Volatility Surging for Eleven Biotherapeutics (EBIO) Stock Options

    Investors in Eleven Biotherapeutics (EBIO) need to pay close attention to the stock based on moves in the options market lately.

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch: Midatech Pharma and Eleven Biotherapeutics

    NEW YORK, NY / ACCESSWIRE / May 3, 2018 / There was no catalyst or news to send shares of both Midatech and Eleven Biotherapeutics higher on Wednesday. Midatech Pharma Plc shares closed up 10.56% yesterday with more gains seen in after-hours trading as well. There was no significant news from the specialty pharmaceutical company to explain the move up.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Trending Tickers: Eleven Biotherapeutics and CVS Health

    NEW YORK, NY / ACCESSWIRE / April 23, 2018 / U.S. markets dropped Friday as positive corporate earnings were offset by losses from the technology and consumer staples sectors. The yield on the 10-year ...

  • Who Are The Largest Shareholders In Eleven Biotherapeutics Inc (NASDAQ:EBIO)?
    Simply Wall St.6 months ago

    Who Are The Largest Shareholders In Eleven Biotherapeutics Inc (NASDAQ:EBIO)?

    In this article, I’m going to take a look at Eleven Biotherapeutics Inc’s (NASDAQ:EBIO) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • Eleven Biotherapeutics (EBIO) in Focus: Stock Moves 8.7% Higher
    Zacks6 months ago

    Eleven Biotherapeutics (EBIO) in Focus: Stock Moves 8.7% Higher

    Shares of Eleven Biotherapeutics (EBIO) rose nearly 9% yesterday.

  • ACCESSWIRE6 months ago

    With FDA Filing On The Horizon, NMTC Could Pull an EBIO-Like Move

    Newly public NeuroOne (NMTC) could be one of these movers in 2018 as they plan to file their first FDA medical device submission in the upcoming months. This technology addresses a large market opportunity and could support multiples of upside.

  • Business Wire6 months ago

    New Preclinical Data Highlighting Eleven Biotherapeutics’ DeBouganin Program to be Presented at 2018 AACR Annual Meeting

    Eleven Biotherapeutics, Inc. , a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that preclinical data from the company’s novel, next-generation ADC program using an innovative deBouganin cytotoxic protein payload will be presented during two poster sessions at the 2018 American Association for Cancer Research Annual ...

  • Business Wire7 months ago

    Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress

    Eleven Biotherapeutics, Inc. , a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today reported key pipeline progress and operating results for the quarter and year ended December 31, 2017.

  • Business Wire7 months ago

    Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual Meeting

    Eleven Biotherapeutics, Inc. , a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that preliminary efficacy and safety data from its ongoing Phase 3 VISTA trial of Vicinium™ in patients with non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin have been selected for presentation ...

  • Business Wire7 months ago

    Eleven Biotherapeutics Announces Pricing of $10.0 Million Offering Priced At-the-Market

    Eleven Biotherapeutics, Inc. , a late-stage clinical company advancing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that it has entered into a definitive agreement with several institutional and accredited investors for the purchase of 7,968,128 shares of its common stock, at a purchase price per share of $1.13, for gross proceeds of approximately $9.0 ...

  • Benzinga7 months ago

    For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'

    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO ), a Cambridge, Massachusetts-based developer of targeted protein therapeutics, has been showing promising clinical data for TPT-based cancer treatments. The ...

  • Business Wire7 months ago

    Enrollment Completed in Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer

    Eleven Biotherapeutics, Inc. , a late-stage clinical company advancing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that the company has completed enrollment in the VISTA Phase 3 registration trial of Vicinium™ in patients with non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin .

  • Business Wire8 months ago

    Eleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference

    Eleven Biotherapeutics, Inc. , a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics platform, today announced that Stephen Hurly, president and chief executive officer, will present a company overview at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 12:00 p.m.

  • Business Wire9 months ago

    Eleven Biotherapeutics Appoints Richard Fitzgerald as Chief Financial Officer

    Eleven Biotherapeutics, Inc. , a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics platform, today announced that Richard F.

  • Business Wire10 months ago

    Eleven Biotherapeutics to Present at Biotech Showcase 2018

    Eleven Biotherapeutics, Inc. , a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics platform, today announced that Stephen Hurly, President and Chief Executive Officer, will present a company overview at the 2018 Biotech Showcase in San Francisco, CA on Tuesday, January 9, 2018 at 11:00 a.m.

  • Business Wire10 months ago

    Eleven Biotherapeutics Announces Chief Scientific Officer to Chair a Session at the Antibody Engineering and Therapeutics Meeting

    Eleven Biotherapeutics, Inc. , a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics platform, today announced that Dr.